Literature DB >> 6193338

Androgens and estrogens: their interaction with stroma and epithelium of human benign prostatic hyperplasia and normal prostate.

M Krieg, W Bartsch, M Thomsen, K D Voigt.   

Abstract

Growth and integrity of human prostatic epithelium is strongly dependent upon the adjacent stroma. Furthermore, the human prostate is under the control of sex hormones. Both facts prompted us to compare epithelium with stroma of human benign prostatic hyperplasia (BPH) and normal prostate (NPR) concerning their metabolism, binding and tissue concentrations of androgens and estrogens. In vitro metabolism was analyzed by t.l.c., androgen and estrogen binding sites were determined by a charcoal adsorption technique, androgen and estrogen tissue concentrations were measured by RIA. The main results are--(1) Metabolism: BPH stroma shows 2-3 times higher 5 alpha-reductase activity than epithelium. This high 5 alpha-reductase activity in BPH stroma dictates the differences between unseparated BPH and NPR, in the former the 5 alpha-reductase activity being 2 times higher. The 3 alpha(beta)-hydroxysteroid dehydrogenase (HSDH) activity is more evenly distributed between stroma and epithelium of BPH and NPR. The ratios of 5 alpha-reductase to HSDH activity in the various tissue fractions indicate that the highest enzymatically regulated 5 alpha-dihydrotestosterone (DHT) enrichment must occur in BPH stroma. (2) Tissue concentrations: unseparated BPH contains 2.2 times more DHT than NPR. About 70% of the total DHT content is found in nuclear fractions, whereby the nuclear DHT content of BPH stroma is significantly higher than that of BPH epithelium. In addition, nuclei of BPH stroma contain significantly more estradiol than epithelial nuclei. (3) Binding: the androgen receptor is evenly distributed between epithelium and stroma of BPH, while the estrogen receptor is preferably assayed in BPH stroma. These studies indicate that the BPH stroma is not only a preferential tissue for 5 alpha-reductase activity and DHT enrichment but also for nuclear estradiol accumulation.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6193338

Source DB:  PubMed          Journal:  J Steroid Biochem        ISSN: 0022-4731            Impact factor:   4.292


  8 in total

1.  Bawu decoction () ameliorates benign prostatic hyperplasia in rats.

Authors:  Ji-Hwan Eom; Se-Yun Cheon; Kyung-Sook Chung; Myung-Dong Kim; Hyo-Jin An
Journal:  Chin J Integr Med       Date:  2016-11-12       Impact factor: 1.978

2.  Aromatization of androstenedione to estrogen by benign prostatic hyperplasia, prostate cancer and expressed prostatic secretions.

Authors:  N N Stone; V P Laudone; W R Fair; J Fishman
Journal:  Urol Res       Date:  1987

3.  Direct effects of oestradiol on growth and morphology of the Dunning R3327H prostatic carcinoma.

Authors:  L Daehlin; A Bergh; J E Damber
Journal:  Urol Res       Date:  1987

4.  Androgen receptor and immune inflammation in benign prostatic hyperplasia and prostate cancer.

Authors:  Kouji Izumi; Lei Li; Chawnshang Chang
Journal:  Clin Investig (Lond)       Date:  2014-10-01

Review 5.  Androgen receptor roles in the development of benign prostate hyperplasia.

Authors:  Kouji Izumi; Atsushi Mizokami; Wen-Jye Lin; Kuo-Pao Lai; Chawnshang Chang
Journal:  Am J Pathol       Date:  2013-04-06       Impact factor: 4.307

6.  Etiopathogenesis of benign prostatic hypeprlasia.

Authors:  Jie Tang; Jingchun Yang
Journal:  Indian J Urol       Date:  2009-07

7.  Castration plus oestrogen treatment induces but castration alone suppresses epithelial cell apoptosis in an androgen-sensitive rat prostatic adenocarcinoma.

Authors:  P Westin; A Brändström; J E Damber; A Bergh
Journal:  Br J Cancer       Date:  1995-07       Impact factor: 7.640

8.  Inhibitory effect of rape pollen supercritical CO2 fluid extract against testosterone-induced benign prostatic hyperplasia in rats.

Authors:  Bi-Cheng Yang; Li-Li Jin; Yi-Fang Yang; Kun Li; Dan-Ming Peng
Journal:  Exp Ther Med       Date:  2014-04-14       Impact factor: 2.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.